EVALUATION OF THE EFFICACY AND SAFETY OF COMBINED USE OF FORMOTEROL AND FLUTICASONE PROPIONATE IN THE TREATMENT OF PATIENTS WITH BRON-CHIAL ASTHMA AND COMORBID CORONARY HEART DISEASE
Journal Title: Астма и Аллергия - Year 2019, Vol 1, Issue 2
Abstract
TAim: to evaluate the clinical efficacy and safety of the use of formoterol (Zafiron medicine, «Adamed Pharma S.A» pharmaceutical company) and fluticasone propionate (Flutixon medicine, «Adamed Pharma S.A» pharmaceutical company) taking into account the clinical symptoms of asthma and functional parameters of the heart in patients with asthma and comorbid coronary heart disease. Materials and methods. The study involved 72 patients: 34 men and 38 women aged 39 to 72 years: 13 (18.0 %) persons had not received inhaled corticosteroids (ICS) for at least 3 months, 14 persons (19.4 %) had ICS irregularly, 45 persons (62.5 %) received ICS as monotherapy due to the presence of cardiovascular contraindications. All patients were divided into two groups, depending on the dose of ICS: Group A, 25 subjects receiving a lower dose of ICS — Fluticasone propionate 125 μg 2 times a day; Group B, 57 persons, receiving the highest dose of ICS — Fluticasone propionate 250 μg 2 times day. All patients received formoterol 12 μg twice a day and on demand (additionally no more than 2 capsules per day). The duration of the therapy was 3 onths. Patients were assessed for Asthma Control Test (ACT), quality of life assessment by the St. George Hospital Questionnaire (SGRQ), spirometry, electrocardiography (ECG), including daily monitoring, Doppler echocardiography. Results and discussion. After 3 months of therapy in most patients with asthma, there was a significant decrease in nocturnal, morning and daytime symptoms, decreased need for fast-acting therapy, improved quality of life, and both groups showed a significant improvement in bronchial patency. ECG data in both groups did not show a significant change in heart rate, QT and QTc intervals. The results of the study showed lack of influence of formoterol on the myocardial contractility, inotropic function of the heart, left ventricular ejection fraction in patients with asthma and comorbid coronary artery disease. Conclusions. The use of fluticasone propionate (Flutixon, «Adamed Pharma S.A») in a dose of 125 μg/250 μg and formoterol (Zafiron, «Adamed Pharma S.A») 12 μg 2 times a day with episodic use of formoterol in patients with asthma and comorbid IHD significantly improved the control of asthma symptoms, bronchial patency and quality of life without development of proarrhythmogenic effect and negative influence on the structural and functional parameters of the right and left heart.
Authors and Affiliations
O. O. Krakhmalova, A. Yu. Tokarіeva, Yu. Ye. Kharchenko, O. V. Izmailova
Keywords
Related Articles
- EP ID EP649034
- DOI 10.31655/2307-3373-2019-2-72-79
- Views 119
- Downloads 0
Allergic bronchopulmonary aspergillosis: XXI century. A modern view on the problem
Aspergillus organisms are widely ubiquitous in the environment and can cause a great number of pathological syndromes mainly in immunocom promised patients . However , aspergillosis lesion may occur not only in patie...
NON-CONTROLLED BRONCHIAL ASTHMA: THE CONTEMPORARY CONDITION OF THE PROBLEM
According to modern concepts, BA is a genetically determined disease, heterogeneous in its clinical manifestations, pathophysiological and immunopathological mechanisms, characterized by chronic inflammation of the respi...
NEBULIZED THERAPY: PRACTICAL ASPECTS
Recently, nebulized therapy has become increasingly popular in practical medicine due to the effectiveness, accessibility and appearance of a wide range of nebulized dosage forms. Today the basis of nebulized therapy is...
MANAGEMENT OF PATIENTS WITH ACUTE — TOXICO-ALLERGIC REACTION: ANALYSIS OF CLINICAL EXPERIENCE WITH PRESENTATION OF A SERIOUS CLINICAL CASE
The article summarizes data on the etiology, pathogenesis and clinical manifestations of acute toxico-allergic reactions (ATAR). The analysis of the management of patients with this pathology in the Dnipro Allergological...
PREDICTION OF VIOLATIONS OF PRIMARY AND SECONDARY HEMOSTASIS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
It is known that patients with chronic obstructive pulmonary disease may have deteriorations in both primary and secondary units of haemostasis. Until now, there is no convenient and accessible method to predict haemosta...